69 studies found for:    vismodegib
Show Display Options
Rank Status Study
1 Completed Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
Conditions: Basal Cell Nevus Syndrome;   Gorlin's Syndrome
Interventions: Drug: Vismodegib;   Drug: Aminolevulinic acid %20 topical solution
2 Recruiting Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Conditions: Locally Advanced Basal Cell Carcinoma;   Skin Cancer;   Cutaneous Malignancy
Interventions: Drug: Vismodegib;   Radiation: Radiation therapy
3 Completed
Has Results
Vismodegib for Treatment of Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Interventions: Drug: Vismodegib;   Drug: Placebo
4 Recruiting Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Conditions: Histologically Confirmed Medulloblastoma;   Activation of the Sonic Hedgehog (SHH) Pathway
Interventions: Drug: vismodegib;   Drug: Temozolomide
5 Recruiting A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
Condition: Prostate Cancer
Intervention: Drug: Vismodegib
6 Recruiting Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib
7 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib;   Drug: Bevacizumab;   Drug: Modified FOLFOX;   Drug: FOLFIRI
8 Completed
Has Results
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
Condition: Recurrent Childhood Medulloblastoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vismodegib
9 Completed Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
Condition: Basal Cell Carcinomas
Interventions: Drug: Vismodegib;   Drug: Placebo
10 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Condition: Ovarian Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib
11 Terminated Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Diffuse Large B-cell Lymphoma;   "Indolent" Non-hodgkin Lymphoma;   Primary Central Nervous System Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: Vismodegib
12 Completed Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Vismodegib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
13 Recruiting Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Condition: Skin Basal Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Drug: Vismodegib
14 Completed
Has Results
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
Condition: Adult Medulloblastoma
Interventions: Other: Pharmacological Study;   Drug: Vismodegib
15 Completed
Has Results
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib
16 Completed
Has Results
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Conditions: Ovarian Cancer;   Basal Cell Carcinoma;   Metastatic Colorectal Cancer
Interventions: Drug: Vismodegib;   Drug: FOLFOX;   Drug: FOLFIRI;   Drug: Bevacizumab
17 Terminated Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
Condition: Pontine Glioma
Intervention: Drug: Vismodegib
18 Completed
Has Results
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft Part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Myxoid Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Mesenchymoma;   Adult Malignant Peripheral Nerve Sheath Tumor;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Adult Unclassified Pleomorphic Sarcoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Dermatofibrosarcoma Protuberans;   Gastrointestinal Stromal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Ovarian Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Kaposi Sarcoma;   Recurrent Osteosarcoma;   Recurrent Uterine Corpus Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma;   Unclassified Pleomorphic Sarcoma of Bone
Interventions: Drug: Gamma-Secretase Inhibitor RO4929097;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vismodegib
19 Active, not recruiting Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)
Condition: Basal Cell Carcinoma
Intervention: Drug: ERIVEDGE
20 Active, not recruiting
Has Results
Evaluation of Food Effect on Pharmacokinetics of Vismodegib
Condition: Malignant Neoplasm
Interventions: Other: Pharmacological Study;   Drug: Vismodegib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years